A growing body of research shows that three seemingly separate immune and connective tissue conditions,hypermobile Ehlers-Danlos syndrome (hEDS), postural orthostatic tachycardia syndrome (POTS), and mast cell activation syndrome (MCAS),cluster together far more often than chance would predict. Understanding why these conditions overlap could help patients and doctors recognize patterns earlier and manage symptoms more effectively.

What Are These Three Conditions, and How Common Is the Overlap?

Hypermobile EDS and hypermobility spectrum disorder are connective tissue conditions where the tissue that provides structure to joints, blood vessels, skin, and organs throughout the body doesn't function properly. POTS is a form of dysautonomia, meaning the autonomic nervous system fails to regulate blood pressure and heart rate correctly when you stand up. Mast cell activation syndrome occurs when immune cells called mast cells activate too readily and release excessive inflammatory mediators like histamine and tryptase in response to triggers that wouldn't normally cause problems.

The overlap between these conditions is striking. A 2024 retrospective study using national health records found that people with hEDS are 29.7 times more likely to be diagnosed with POTS than the general population. Among POTS patients specifically, 31% met the full clinical criteria for hEDS, with another 24% showing significant joint hypermobility without meeting all diagnostic criteria.

For mast cell activation syndrome and hEDS, a large retrospective analysis of over 37,000 patients found that nearly one in three people diagnosed with MCAS had a comorbid hEDS diagnosis. Most striking of all, a 2025 study surveyed 84 women with hypermobility spectrum disorder or hEDS and found that 58.3% had POTS, 32.1% had MCAS, and 25% had all three diagnoses simultaneously. That means one in four people with hEDS are living with all three conditions at once.

Why Do These Conditions Cluster Together?

The relationship between these three conditions is real and well-documented, but the precise biological mechanisms are still being worked out. The most intuitive explanation involves the structural problems in connective tissue. In hEDS, blood vessels may be more compliant than normal, meaning they don't constrict efficiently when you stand up. Blood pools in the lower limbs and abdomen, the body's pressure sensors detect a drop in effective circulating volume, and the heart races to compensate. This is one proposed mechanism for why POTS is more common in hEDS.

Mast cells live throughout connective tissue, particularly at tissue-environment interfaces like the gut, skin, and respiratory tract. If the connective tissue is structurally abnormal in hEDS, the environment where mast cells live may be altered too. A 2022 review found that mast cell mediators, particularly histamine and tryptase, can directly disrupt connective tissue integrity through activity across multiple organ systems. This suggests a bidirectional relationship: abnormal connective tissue affects the mast cell environment, and activated mast cells further disrupt connective tissue.

Emerging research also points to mechanobiology, the study of how physical forces on cells affect their signaling behavior. A 2022 paper in Frontiers in Cell and Developmental Biology explored how altered tissue mechanics in EDS might drive mast cell dysregulation through mechanobiological pathways. While this evidence is largely theoretical at this stage, the direction is promising for understanding the deeper connections between these conditions.

How to Recognize and Manage the Trifecta

If you've been diagnosed with one of these conditions, here are key steps to take:

• Get screened for all three: Because the overlap is so common, ask your doctor about testing for the other two conditions if you have one. A 2025 study in Frontiers in Neurology found that diagnostic definitions matter significantly, so working with specialists familiar with all three is important.
• Track your triggers carefully: Mast cell activation can be triggered by foods, smells, temperature changes, stress, exercise, and medications. Keeping a detailed symptom diary helps identify patterns and avoid triggers that worsen your condition.
• Understand the diagnostic window: Many mast cell mediators degrade quickly, so testing needs to happen at the right time. Tryptase, the most stable marker, has a short half-life, and urinary N-methyl histamine and prostaglandin D2 can also be measured, but the diagnostic window is narrow.
• Work with a multidisciplinary team: Because these conditions affect multiple body systems, coordinating care between cardiologists, rheumatologists, immunologists, and other specialists is essential for effective management.

What Remains Uncertain?

While the clustering of these three conditions is undeniable, researchers emphasize that the exact biological pathways connecting them are still being confirmed experimentally. The overlap is real and documented, but the mechanisms are proposed and plausible rather than definitively proven. A 2025 study in Autonomic Neuroscience noted that how strictly you define each condition changes the prevalence numbers significantly, but the association holds up regardless of which diagnostic definitions are applied.

The good news is that recognition of this pattern is improving. Patients who understand they may have multiple conditions are better equipped to advocate for comprehensive testing and coordinated care. As research continues to clarify the biological connections, treatment approaches may become more targeted and effective for people living with this challenging combination of conditions.